Amicus Therapeutics, Inc. FOLD
Set alert
14.49 USD 0.00 0.00%
At close · Apr 27
14.49 0.00 0.00%
After hours · Apr 27, 4:00 PM ET
14.49 Day range 14.49
8.62 52-week range 14.50
- YTD
- +1.76%
- 1 year
- +97.14%
- Open
- 14.49
- Prev close
- 14.49
- Mkt cap
- 4.55B
- Vol
- 0
- Avg vol
- 2.62M
- EPS
- -0.08
- P/E
- -783.24
- Div yield
- 0.00%
More statistics
- Low
- 14.49
- High
- 14.49
- Beta
- 0.48
- Inst. own
- 104.39%
- Dividend
- 0.00
- Earnings
- May 7, 2026
2Y chart
Events in this range
- Feb 19, 2025Earnings: 0.09; estimate 0.02; surprise 350%
- May 1, 2025Earnings: -0.07; estimate 0.01; surprise -800%
- Jul 31, 2025Earnings: -0.08; estimate -0.05; surprise -60%
- Nov 4, 2025Earnings: 0.06; estimate 0.03857; surprise 55.56%
- Dec 17, 2025Rating: Citigroup · — → Buy
- Dec 19, 2025Downgrade: Cantor Fitzgerald · Overweight → Neutral
- Dec 19, 2025Downgrade: Needham · Buy → Hold
- Dec 22, 2025Downgrade: Citigroup · Buy → Neutral
- Dec 29, 2025Downgrade: Leerink Partners · Outperform → Market Perform
- Jan 22, 2026Downgrade: Jefferies · Buy → Hold
- Feb 20, 2026Earnings: 0.01; estimate 0.07143; surprise -86%
Signals (75)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Apr 24, 2026 | 6 months ago |
| RSI: Overbought | Apr 7, 2026 | 6 months ago |
| RSI: Overbought | Mar 31, 2026 | 7 months ago |
| RSI: Overbought | Mar 19, 2026 | 7 months ago |
| RSI: Overbought | Mar 9, 2026 | 7 months ago |
| MACD: Sell Signal | Jan 8, 2026 | 9 months ago |
| MACD: Buy Signal | Dec 12, 2025 | 10 months ago |
| RSI: Overbought | Dec 12, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 2, 2025 | 11 months ago |
| RSI: Overbought | Nov 26, 2025 | 11 months ago |
| RSI: Overbought | Nov 19, 2025 | 11 months ago |
| MACD: Buy Signal | Oct 22, 2025 | 1 year ago |
| SMA: Bullish | Oct 2, 2025 | 1 year ago |
| SMA: Bearish | Oct 1, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 23, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 22, 2025 | 1 year ago |
| RSI: Overbought | Sep 22, 2025 | 1 year ago |
| RSI: Overbought | Sep 18, 2025 | 1 year ago |
| SMA: Bullish | Sep 16, 2025 | 1 year ago |
| SMA: Bearish | Sep 15, 2025 | 1 year ago |
| RSI: Overbought | Sep 11, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 10, 2025 | 1 year ago |
| SMA: Bullish | Sep 4, 2025 | 1 year ago |
| RSI: Overbought | Sep 2, 2025 | 1 year ago |
| RSI: Overbought | Aug 21, 2025 | 1 year ago |
| SMA: Bullish | Aug 1, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 1, 2025 | 1 year ago |
| SMA: Bearish | Jul 31, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 31, 2025 | 1 year ago |
| SMA: Bullish | Jul 28, 2025 | 1 year ago |
| SMA: Bearish | Jul 25, 2025 | 1 year ago |
| SMA: Bullish | Jul 22, 2025 | 1 year ago |
| SMA: Bearish | Jul 18, 2025 | 1 year ago |
| SMA: Bullish | Jul 17, 2025 | 1 year ago |
| SMA: Bearish | Jul 15, 2025 | 1 year ago |
| SMA: Bullish | Jul 14, 2025 | 1 year ago |
| SMA: Bearish | Jul 11, 2025 | 1 year ago |
| SMA: Bullish | Jul 8, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 18, 2025 | 1 year ago |
| MACD: Buy Signal | May 16, 2025 | 1 year ago |
| RSI: Oversold | May 7, 2025 | 1 year ago |
| MACD: Sell Signal | May 6, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 22, 2025 | 1 year ago |
| RSI: Oversold | Apr 16, 2025 | 1 year ago |
| RSI: Oversold | Apr 1, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 25, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 17, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 20, 2025 | 1 year ago |
| SMA: Bearish | Feb 19, 2025 | 1 year ago |
| SMA: Bullish | Feb 13, 2025 | 1 year ago |
| SMA: Bullish | Feb 3, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 16, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 31, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 2, 2024 | 1 year ago |
| RSI: Oversold | Nov 15, 2024 | 1 year ago |
| SMA: Bearish | Nov 7, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 6, 2024 | 1 year ago |
| SMA: Bullish | Oct 17, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 16, 2024 | 2 years ago |
| RSI: Oversold | Oct 10, 2024 | 2 years ago |
| RSI: Oversold | Oct 7, 2024 | 2 years ago |
| SMA: Bearish | Sep 25, 2024 | 2 years ago |
| SMA: Bearish | Sep 18, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 28, 2024 | 2 years ago |
| RSI: Overbought | Aug 20, 2024 | 2 years ago |
| RSI: Overbought | Aug 13, 2024 | 2 years ago |
| SMA: Bullish | Aug 8, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 8, 2024 | 2 years ago |
| SMA: Bearish | Aug 2, 2024 | 2 years ago |
| SMA: Bullish | Jul 31, 2024 | 2 years ago |
| SMA: Bearish | Jul 30, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 23, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 8, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 20, 2024 | 2 years ago |
Key statistics
- Market cap
- 4.55B
- Enterprise value
- 4.82B
- Trailing P/E
- -783.24
- PEG ratio
- 8.04
- Price / sales
- 8.94
- Price / book
- 16.33
- Beta
- 0.48
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -1.07%
- Total cash
- 0
- Total debt
- 2
- Return on equity
- -2.30%
Analyst view
Price target (mean) —
Ratings (0m) 12 9 buy · 3 hold · 0 sell
- Strong buy8
- Buy1
- Hold3
- Sell0
- Strong sell0
Next earnings
May 7, 2026
Expected May 7, 2026. Consensus EPS estimate 0.1811.
Financials — quick view
FOLD Revenue — quarterly 185.21M
FOLD Net income — quarterly 1.69M
FOLD EPS — quarterly 0.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 7, 2026 | Mar 31, 2026 | 0.04667 | — | — | — |
| Feb 20, 2026 | Dec 31, 2025 | 0.07143 | 0.01 | -0.06 | -86.00% |
| Nov 4, 2025 | Sep 30, 2025 | 0.03857 | 0.06 | +0.02 | +55.56% |
| Jul 31, 2025 | Jun 30, 2025 | -0.05 | -0.08 | -0.03 | -60.00% |
| May 1, 2025 | Mar 31, 2025 | 0.01 | -0.07 | -0.08 | -800.00% |
| Feb 19, 2025 | Dec 31, 2024 | 0.02 | 0.09 | +0.07 | +350.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 22, 2026 | Jefferies | down | Buy | Hold |
| Dec 29, 2025 | Leerink Partners | down | Outperform | Market Perform |
| Dec 22, 2025 | Citigroup | down | Buy | Neutral |
| Dec 19, 2025 | Needham | down | Buy | Hold |
| Dec 19, 2025 | Cantor Fitzgerald | down | Overweight | Neutral |
| Dec 17, 2025 | Citigroup | init | — | Buy |
About Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 499
- Website
- amicusrx.com
News
- Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks
- This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold
- BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition
- CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)
- BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy
- SG Americas Securities LLC Acquires 36,938 Shares of Amicus Therapeutics, Inc. $FOLD
- Capricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLD
- Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications
- Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD
- Microsoft files amicus brief in support of Anthropic's lawsuit with US DOD
Your note
Sign in to keep a note on FOLD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BLEIL LYNN DORSEY | Director | Stock Award(Grant) | Jun 4, 2025 | 113,941 |
| CAMPBELL BRADLEY LEWIS | Chief Executive Officer | Sale | Mar 1, 2026 | 998,680 |
| CASTELLI JEFFREY P | Officer | Sale | Nov 23, 2025 | 439,318 |
| CLARK DAVID MICHAEL | Officer | Sale | Dec 18, 2025 | 245,690 |
| HARFORD SIMON N R | Chief Financial Officer | Stock Award(Grant) | Jan 2, 2025 | 227,427 |
| PROUT SAMANTHA WHITEMAN | Officer | Stock Award(Grant) | Nov 30, 2025 | 141,634 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BlackRock Inc | 10.79% | 33,879,048 | 0 | Mar 30, 2026 |
| Vanguard Group Inc | 9.46% | 29,702,696 | 0 | Dec 30, 2025 |
| UBS Group AG | 5.08% | 15,957,913 | 0 | Mar 30, 2026 |
| Vanguard Capital Management, LLC | 4.47% | 14,023,557 | 0 | Mar 30, 2026 |
| Pentwater Capital Management LP | 4.46% | 14,000,000 | 0 | Mar 30, 2026 |
| Vanguard Portfolio Management, LLC | 4.45% | 13,974,932 | 0 | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Canadian Large Cap Sr B | 1.42% | 4,460,000 | 0 | Mar 30, 2026 |
| Fidelity Small Cap Index | 0.93% | 2,913,264 | 0 | Mar 30, 2026 |
| Nomura US Small Cap Core Equity | 0.91% | 2,842,566 | 0 | Mar 30, 2026 |
| Fidelity Global Value Long/Short F | 0.82% | 2,575,000 | 0 | Mar 30, 2026 |
| Fidelity Canadian Large Cp Mlt Ast Bs O | 0.68% | 2,123,028 | 0 | Mar 30, 2026 |
| Pictet Biopharmaceutical Mother | 0.67% | 2,111,724 | 0 | Oct 13, 2025 |